L
Larkspur Biosciences
Precision immunotherapies targeting cancer cell fitness genes
About Larkspur Biosciences
Larkspur Biosciences is a biotechnology firm developing precision immunotherapies designed to overcome cancer's ability to evade the immune system. The company was founded in 2020 by world-class scientists Dr. Lewis Cantley, Dr. Nathanael Gray, and Dr. Vijay K. Kuchroo, whose research into cancer cell biology, biochemistry, and immunology forms the company's scientific foundation. Larkspur launched in May 2023 with $35.5 million in a combined seed and Series A financing round led by Polaris Innovation Fund, 3E Bioventures Capital, and Takeda Ventures, Inc.
The company’s primary business is the discovery and development of small molecule medicines that target cancer cell fitness genes. This approach aims to make cancer cells more vulnerable to being destroyed by the body's own immune mechanisms. Larkspur's proprietary discovery platform, LarkX, utilizes patient genetics, immune phenotypes, and machine learning to identify new therapeutic targets and predict patient populations most likely to respond to treatment. The business model centers on advancing its pipeline of drug candidates through preclinical and clinical studies, with the ultimate goal of commercializing these therapies or forming strategic partnerships with larger pharmaceutical companies.
Larkspur is advancing several first-in-class programs. Its lead program involves a novel approach to lipid remodeling to make tumors more visible to the immune system. Another key program targets Pin1, a protein involved in fibroblast differentiation, to create a more pro-immune tumor microenvironment. The company is initially focused on a specific subtype of colorectal cancer (CRC) for proof-of-concept studies. Additionally, Larkspur is developing a program targeting the B cell checkpoint TIM-1, based on foundational research from co-founder Dr. Vijay K. Kuchroo, which aims to leverage B cells to enhance anti-tumor responses.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | May 2023 | $25M | $99M | Takeda Ventures · 3E Bioventures · Polaris Partners · Creacion Ventures | ↗ |
| SEED✓Equity / VC | Nov 2022 | $11M | $43M | Creacion Ventures · Cornell University · Med-Fine Capital · Polaris Partners | ↗ |
Growth signals
Latest recorded traffic for Larkspur Biosciences is 910 monthly website visits, down 52.1% over the last three months. Larkspur Biosciences's team grew 5.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Larkspur Biosciences in the Cambridge ecosystem
The Larkspur Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed6 investors entered at this stage
Polaris Partners
Takeda Ventures
3E Bioventures- CVCreacion Ventures
Cornell University
Med-Fine Capital
Other known investors1 additional known investor
Cornell Tech
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Larkspur Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Larkspur Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








